Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9662315 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
May, 2029
(5 years from now) | |
US9408837 | PURPLE BIOTECH | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
Feb, 2030
(5 years from now) | |
US10945960 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) | |
US10925835 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) | |
US10350171 | PURPLE BIOTECH | Celecoxib and amlodipine formulation and method of making the same |
Jun, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | May 31, 2021 |
Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate
Dosage: TABLET;ORAL